Inactivated quadrivalent influenza vaccine: time to double the dose in young children?

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In children aged 6-17 mo, double-dose inactivated quadrivalent influenza vaccine (IIV4) demonstrated immunogenic noninferiority compared to standard-dose for all strains, with selective superior immunogenicity for B strains in a post hoc analysis.

Why this matters

  • Primary requirement for US licensure criteria was demonstrated, supporting a potential future change in clinical practice toward double-dose IIV4 in all children aged 6 mo and older.

Study design

  • Phase 3, randomized, controlled, observer-blind, multicenter trial.
  • Children aged 6-35 mo (2014-15 season).
  • Vaccinated with investigational double-dose IIV4 or United States-approved standard-dose IIV4.
  • Double-dose contained 15 μg hemagglutinin (HA) of each of: A/California/7/2009 (A/H1N1), A/Texas/50/2012 (A/H3N2), B/Brisbane/60/2008 (B/Victoria), and B/Massachusetts/2/2012 (B/Yamagata).
  • Standard dose contained 7.5 μg of HA of each.
  • Funding: GlaxoSmithKline Biologicals SA.

Key results

  • 2424 children in intent-to-treat cohort.
  • Immunogenic noninferiority of double vs standard dose was demonstrated 28 d after vaccination for all strains in terms of geometric mean titers and seroconversion.
  • Post hoc analysis showed superior immunogenicity for double vs standard dose against B strains in children 6-17 mo of age and unprimed children.
  • Safety and reactogenicity were similar for both doses.